Buy Visomitin (SkQ1) 5ml bottle
Active ingredient: Plastoquinonyldecyltriphenylphosphonium bromide
Free Shipping
Without prescription
1 bottle x 5ml
A
few years ago a small molecule SkQ1 was synthesized by the group of professor
Vladimir P. Skulachev in the Moscow State University. One part of SkQ1
functions as a molecular “tow truck” carrying the other part of the molecule –
an extremely active antioxidant plastoquinone – into mitochondria. Both
theoretical calculations and experimental results showed that SkQ1 was
delivered into the mitochondria in an extremely targeted and efficient manner.
The physics of the mitochondrial membrane and the unique properties of SkQ1
direct it into the inner leaflet of the inner mitochondrial membrane with high
precision.
The
presence of SkQ1 in mitochondrial membrane enables mitochondria to protect
itself from reactive oxygen species (ROS) by breaking the chain reaction of
lipid destruction. This ability of the lead molecule to protect cells against
oxidative stress is the key
in treating patients suffering from various age-related disorders such
as cardiovascular diseases, neurodegenerative disorders and ophthalmic
conditions.
It
has been hypothesized that age-dependent accumulation of oxidative damages in
living organisms may be the main cause of ageing process. It might be possible
to control this damage accumulation through controlling the level of ROS
production in mitochondria. It is important to stress that ROS production
should be controlled, not stopped, so that ROS can still fulfill a number of
crucial biological functions. For instance they fight bacteria and viruses,
both directly – via elimination of pathogens, – and indirectly – via regulation
of the immunological response to infection through triggering apoptosis (cell
death).
Antioxidants
are a well−developed pharmacological approach to fight against ROS. A possible
role of antioxidants in controlling ageing process has widely and for a long
time been discussed with ambiguous conclusions, ranging from the statement of
the American biochemist Prof. Bruce Ames and colleagues on finding a new
anti−ageing therapy with a 100% positive result to D. Howes’s implication of
the utter barrenness of this method, and, therefore, of total failure of
Harman’s “free radical” hypothesis. According to Dr. Skulachev the
antioxidant−based ageing control approach has some significant flaws.
The
“ideal” antioxidant should be specifically targeted to mitochondria where ROS
are produced and it should effectively remove not all the ROS but just their
excess. It is also important for an antioxidant not to be toxic and not to be
recognized and eliminated by cell enzymes.
With
these criteria fulfilled, a successful anti-oxidant compound should be able to
prevent/repair oxidative damage in organism and prevent/treat many age-related
disorders across various therapeutic areas.
The mechanism of action of SkQ1 involves at least two extremely complex
and novel concepts: delivering a compound inside mitochondria and reducing ROS
production inside mitochondria in a controlled and sustainable manner. SkQ1
molecule successfully addresses these two aspects as our experimental work has
shown.
More
than a dozen studies have been conducted and showed SkQ1 effectiveness in
such critical therapeutic areas as
the following:
o Age-related macular degeneration (AMD)
o Dry eye
syndrome (DES)
o Non-infectious
uveitis
o Cataract
o Glaucoma
Country of Manufacture: Russia
Note: the product should be kept in the fridge after
receiving.
One of the reasons for the development of age-related
cataracts is the damaging effect of ultraviolet radiation, which initiates
photo-oxidation processes, leading to denaturation of the main structural
component of the lens - crystallins. The first protection of eye tissue from
ultraviolet radiation is tear fluid, which absorbs ultraviolet light in the
range of 240-320 nm and neutralizes it due to the components of the antioxidant
activity of the tear fluid. According to preclinical studies, the anti-cataract
effect of Vizomitin® is associated with an increase in the level of expression
of the main proteins of? -Crystalline lenses, restoration of the lens
epithelium and activation of energy processes in it. According to a clinical
study, patients with age-related cataracts who used Vizomitin® had an increase
in the antioxidant activity of tears.
Dosage
Dry eye syndrome: 1-2 drops of the drug in the
conjunctival sac 3 times a day. The duration of treatment is determined by the
doctor depending on the severity of the disease. The initial stage of
age-related cataracts: 1-2 drops of the drug in the conjunctival sac 3 times a
day. Duration of treatment is 6 months. During drug therapy, an ophthalmologist
should be monitored to assess the degree of disease progression and the need to
continue conservative therapy.
Overdose
Data on overdose for local use are not available.
Visomitin (SkQ1) for sale: No prescription is required, but a valid prescription or doctor's recommendation is assumed. Please don't heal yourself. Get expert advice before buying Visomitin (SkQ1).
The drug images are only for illustration purposes and may not exactly represent real product. This product is for the Russian market and can be labeled in Russian (package design may vary). To make sure you're buying the right product, use Google Translate to translate the word Визомитин into English. Just copy and paste.
VISOMITIN EYE DROPS SkQ1 5ml
- Product Code: SkQ1-5
- Availability: In Stock
-
$38.96
- Ex Tax: $38.96